Idose Tr is a drug owned by Glaukos Corp. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 17, 2030. Details of Idose Tr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11426306 | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(5 years from now) | Active |
| US10206813 | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Idose Tr's patents.
Latest Legal Activities on Idose Tr's Patents
Given below is the list of recent legal activities going on the following patents of Idose Tr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 30 Aug, 2022 | US11426306 |
| Patent Issue Date Used in PTA Calculation Critical | 30 Aug, 2022 | US11426306 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Aug, 2022 | US10206813 |
| Email Notification Critical | 11 Aug, 2022 | US11426306 |
| Issue Notification Mailed Critical | 10 Aug, 2022 | US11426306 |
| Dispatch to FDC | 29 Jul, 2022 | US11426306 |
| Workflow - Drawings Finished | 28 Jul, 2022 | US11426306 |
| Email Notification Critical | 03 Jun, 2022 | US11426306 |
| Mail PUB other miscellaneous communication to applicant | 03 Jun, 2022 | US11426306 |
| PUB Other miscellaneous communication to applicant | 01 Jun, 2022 | US11426306 |
FDA has granted several exclusivities to Idose Tr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Idose Tr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Idose Tr.
Exclusivity Information
Idose Tr holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Idose Tr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
US patents provide insights into the exclusivity only within the United States, but Idose Tr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Idose Tr's family patents as well as insights into ongoing legal events on those patents.
Idose Tr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Idose Tr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 17, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Idose Tr Generic API suppliers:
Travoprost is the generic name for the brand Idose Tr. 8 different companies have already filed for the generic of Idose Tr, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Idose Tr's generic
Alternative Brands for Idose Tr
There are several other brand drugs using the same active ingredient (Travoprost) as Idose Tr. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alcon Pharms Ltd |
| |
| Novartis |
| |
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Travoprost, Idose Tr's active ingredient. Check the complete list of approved generic manufacturers for Idose Tr
About Idose Tr
Idose Tr is a drug owned by Glaukos Corp. Idose Tr uses Travoprost as an active ingredient. Idose Tr was launched by Glaukos in 2023.
Approval Date:
Idose Tr was approved by FDA for market use on 13 December, 2023.
Active Ingredient:
Idose Tr uses Travoprost as the active ingredient. Check out other Drugs and Companies using Travoprost ingredient
Dosage:
Idose Tr is available in implant form for intracameral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75MCG | IMPLANT | Prescription | INTRACAMERAL |